Insys to file NDA for synthetic cannabinoid solution this quarter

Insys Therapeutics (INSY) plans to file an NDA this quarter for Dronabinol Oral Solution for the treatment of chemotherapy-induced nausea and vomiting and for the treatment of anorexia in patients with AIDS.

Dronabinol is currently off patent and available in a soft gelatin capsule form. The oral solution has a faster onset of action and will enable physicians to titrate patients more precisely.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs